Management of Influenza-Like Illness

Antiviral Treatment Criteria

The American Thoracic Society recommends initiating oseltamivir only if all three criteria are met: acute influenza-like illness, fever >38°C, and symptomatic for ≤48 hours 1
The British Thoracic Society suggests that oseltamivir should be initiated within 48 hours of symptom onset for patients with influenza-like illness and fever >38°C 1, 2

Antibiotic Management: Stratified by Severity

The Infectious Diseases Society of America recommends that previously healthy adults with acute bronchitis complicating influenza do not require antibiotics unless they develop worsening symptoms 1, 3
The American College of Chest Physicians suggests that antibiotics should be considered only if worsening symptoms develop or if the patient is at high risk of complications and has lower respiratory tract features 1, 3
The European Respiratory Society recommends co-amoxiclav as the first-line oral antibiotic for patients with influenza-related pneumonia 1, 3

Antibiotic Duration and Route Switching

The Infectious Diseases Society of America recommends switching from IV to oral antibiotics when clinical improvement occurs, temperature is normal for 24 hours, and there is no contraindication to the oral route 1, 3
The American College of Chest Physicians suggests that the duration of antibiotic therapy should be 7 days for non-severe, uncomplicated pneumonia, 10 days for severe, microbiologically undefined pneumonia, and 14-21 days for confirmed/suspected S. aureus or Gram-negative pneumonia 1, 3

Supportive Care

The World Health Organization recommends that all patients with influenza-like illness should receive antipyretics for fever control, adequate hydration, and avoid aspirin in children due to the risk of Reye's syndrome 3

Treatment of Viral Pneumonia Due to Influenza

Antiviral Therapy

Hospitalized patients with severe illness benefit from oseltamivir even when started >48 hours after symptom onset, particularly if immunocompromised 4
Zanamivir (inhaled) is an alternative neuraminidase inhibitor for patients unable to take oseltamivir 5

Antibiotic Therapy

Previously healthy adults with influenza-related pneumonia without bacterial features do not routinely require antibiotics 4
Add antibiotics immediately if any of the following are present: worsening symptoms after initial improvement, high-risk patients with lower respiratory tract features, or confirmed or suspected bacterial pneumonia on imaging or clinical grounds 4
First-line oral therapy for non-severe influenza-related pneumonia: co-amoxiclav or tetracycline 4
Immediate parenteral combination therapy for severe influenza-related pneumonia: IV co-amoxiclav or 2nd/3rd generation cephalosporin (cefuroxime, cefotaxime) PLUS a macrolide (clarithromycin or erythromycin) 4
Antibiotics must be administered within 4 hours of admission 4
Switch from IV to oral antibiotics when clinical improvement occurs, temperature normal for 24 hours, and oral route feasible 4
Duration: 7 days for non-severe, uncomplicated pneumonia; 10 days for severe, microbiologically undefined pneumonia 4

Special Considerations

The American Thoracic Society and Infectious Diseases Society of America recommend that hospitalized and severely ill patients benefit from oseltamivir even when treatment starts >48 hours after symptom onset 4
The Centers for Disease Control and Prevention suggest that Zanamivir (inhaled) is an alternative neuraminidase inhibitor for patients unable to take oseltamivir 5

Influenza Management and Clinical Presentation

Diagnosis and Treatment

The American Thoracic Society recommends initiating oseltamivir 75 mg orally every 12 hours for 5 days if acute influenza-like illness, fever >38°C, and symptomatic ≤48 hours are present 6, 7
Hospitalized or severely ill patients should still receive oseltamivir even if >48 hours from onset, particularly if immunocompromised 6, 7
Supportive care remains the mainstay: antipyretics, rest, adequate hydration 6, 8, 9

Special Populations

The American Academy of Pediatrics recommends that aspirin is absolutely contraindicated in children <16 years due to Reye's syndrome risk 8, 9
Children <1 year and those at high risk should be assessed by a physician 8, 9
The Infectious Diseases Society of America recommends that elderly and immunocompromised patients may not mount adequate febrile response but still eligible for antiviral treatment 6, 7

Clinical Predictors and Red Flags

Red flags requiring re-consultation include shortness of breath at rest, painful or difficult breathing, coughing up bloody sputum, recrudescent fever, increasing dyspnea, altered mental status, and inability to maintain oral intake 6, 7, 8
The European Respiratory Society recommends watching for warning signs of complications, such as recrudescent fever, at the early recovery phase 6, 8

Antiviral Therapy

For a patient with pneumonia who tests positive for influenza, oseltamivir 75 mg orally twice daily for 5 days should be added to the treatment regimen, as recommended by the Infectious Diseases Society of America 10

Antibiotic Regimens

The current azithromycin monotherapy is inadequate for influenza-related pneumonia, and co-amoxiclav (amoxicillin-clavulanate) or a similar antibiotic should be added to the regimen as first-line therapy, according to the British Thoracic Society 11, 12
For non-severe pneumonia, switching to co-amoxiclav or adding it to the regimen is recommended, with alternative options including tetracycline (doxycycline) 11
For severe pneumonia, immediate IV combination therapy with co-amoxiclav or a 2nd/3rd generation cephalosporin (cefuroxime or cefotaxime) PLUS a macrolide (clarithromycin or azithromycin) is required, with antibiotics administered within 4 hours of admission 11, 12

Antibiotic Duration

The antibiotic duration should be 7 days total for non-severe, uncomplicated pneumonia, 10 days for severe, microbiologically undefined pneumonia, and 14-21 days if S. aureus or Gram-negative bacteria are confirmed or strongly suspected, as recommended by the British Thoracic Society 12

Route Switching Strategy

Switching from IV to oral antibiotics is recommended when clinical improvement occurs, temperature normal for 24 hours, and oral route is feasible, according to the British Thoracic Society 12

Management of Influenza‑Like Illness in Adults with Asthma (Cited Evidence)

Antiviral Therapy

Oseltamivir should not be prescribed for an outpatient who presents ≥ 48 hours after symptom onset because clinical benefit is only established within the first 48 hours. 13
In hospitalized patients or those who are immunocompromised, antiviral therapy may still be considered even after 48 hours. 13

Antibiotic Indications

Routine antibiotics are not required for previously healthy adults with acute bronchitis secondary to influenza when there is no radiographic pneumonia. [14][15]
Asthma increases the risk of influenza‑related complications, warranting closer observation for bacterial superinfection. 16
Initiate antibiotics promptly if any of the following develop:
- Recrudescent fever or worsening dyspnea. [14][15]
- New lower‑respiratory‑tract signs such as focal chest findings, purulent sputum, or chest tightness beyond the patient’s baseline asthma. [14][13]

First‑Line Antibiotic Choice (When Indicated)

Preferred oral agents are co‑amoxiclav or doxycycline, which provide coverage for Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and importantly Staphylococcus aureus—a key pathogen in influenza‑associated bacterial pneumonia. [14][13][15][17]
If the patient is penicillin‑intolerant, clarithromycin or erythromycin are acceptable alternatives. [14][15]17

Supportive Care & Asthma Management

Ensure optimal asthma control by confirming correct use of maintenance inhalers and availability of a rescue inhaler. 16

Red‑Flag Symptoms Requiring Urgent Re‑evaluation

Return or call immediately for recrudescent fever after an initial improvement, as this may signal bacterial superinfection. [14][15]

Common Pitfalls to Avoid

Do not prescribe oseltamivir at day 4 in an outpatient with uncomplicated illness; evidence of benefit does not extend beyond 48 hours. 13
Do not start antibiotics empirically in the absence of clear bacterial infection features, even in patients with asthma; adopt a watch‑and‑wait approach with clear return precautions. [14][15]
Recognize that asthma places the patient at higher risk for complications and therefore requires closer monitoring than a previously healthy adult. 16